Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Melanoma 31Neoplasms 17Multiple Myeloma 9Thyroid Neoplasms 8Hematologic Neoplasms 7Thyroid Carcinoma, Anaplastic 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Lymphoma 5Glioma 5Colorectal Neoplasms 5Thyroid Cancer, Papillary 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Skin Neoplasms 2Neurofibroma, Plexiform 2Neoplasm Metastasis 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

Rituximab 12Tacrolimus 11Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 9fludarabine phosphate 8Cyclophosphamide 8Whole-Body Irradiation 6Methotrexate 5Cyclosporine 5Antilymphocyte Serum 5Vemurafenib 4Methylprednisolone 4Cladribine 4Busulfan 4merphos 3Therapeutics 3Radiotherapy 3Alemtuzumab 3obinutuzumab 2ibrutinib 2fludarabine 2binimetinib 2aldesleukin 2Transplantation 2Specimen Handling 2Prednisone 2Melphalan 2Lenalidomide 2Interferon-alpha 2Filgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Hairy Cell × trametinib × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡